key: cord-0906462-z0a9o7ke
authors: Garcia, Santiago; Dehghani, Payam; Grines, Cindy; Davidson, Laura; Nayak, Keshav R.; Saw, Jacqueline; Waksman, Ron; Blair, John; Akshay, Bagai; Garberich, Ross; Schmidt, Christian; Ly, Hung Q.; Sharkey, Scott; Mercado, Nestor; Alfonso, Carlos E.; Misumida, Naoki; Acharya, Deepak; Madan, Mina; Hafiz, Abdul Moiz; Javed, Nosheen; Shavadia, Jay; Stone, Jay; Alraies, M. Chadi; Htun, Wah; Downey, William; Bergmark, Brian A.; Ebinger, Jospeh; Alyousef, Tareq; Khalili, Houman; Hwang, Chao-Wei; Purow, Joshua; Llanos, Alexander; McGrath, Brent; Tannenbaum, Mark; Resar, Jon; Bagur, Rodrigo; Cox-Alomar, Pedro; Stefanescu Schmidt, Ada C.; Cilia, Lindsey A.; Jaffer, Farouc A.; Gharacholou, Michael; Salinger, Michael; Case, Brian; Kabour, Ameer; Dai, Xuming; Elkhateeb, Osama; Kobayashi, Taisei; Kim, Hahn-Ho; Roumia, Mazen; Aguirre, Frank V.; Rade, Jeffrey; Chong, Aun-Yeong; Hall, Hurst M.; Amlani, Shy; Bagherli, Alireza; Patel, Rajan A.G.; Wood, David A.; Welt, Frederick G.; Giri, Jay; Mahmud, Ehtisham; Henry, Timothy D.
title: Initial Findings From the North American COVID-19 Myocardial Infarction Registry
date: 2021-04-27
journal: J Am Coll Cardiol
DOI: 10.1016/j.jacc.2021.02.055
sha: af7a6e6ce59d0a5e8d170ae1ca0a90b52d3328c4
doc_id: 906462
cord_uid: z0a9o7ke

BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic has impacted many aspects of ST-segment elevation myocardial infarction (STEMI) care, including timely access to primary percutaneous coronary intervention (PPCI). OBJECTIVES: The goal of the NACMI (North American COVID-19 and STEMI) registry is to describe demographic characteristics, management strategies, and outcomes of COVID-19 patients with STEMI. METHODS: A prospective, ongoing observational registry was created under the guidance of 3 cardiology societies. STEMI patients with confirmed COVID+ (group 1) or suspected (person under investigation [PUI]) (group 2) COVID-19 infection were included. A group of age- and sex-matched STEMI patients (matched to COVID+ patients in a 2:1 ratio) treated in the pre-COVID era (2015 to 2019) serves as the control group for comparison of treatment strategies and outcomes (group 3). The primary outcome was a composite of in-hospital death, stroke, recurrent myocardial infarction, or repeat unplanned revascularization. RESULTS: As of December 6, 2020, 1,185 patients were included in the NACMI registry (230 COVID+ patients, 495 PUIs, and 460 control patients). COVID+ patients were more likely to have minority ethnicity (Hispanic 23%, Black 24%) and had a higher prevalence of diabetes mellitus (46%) (all p < 0.001 relative to PUIs). COVID+ patients were more likely to present with cardiogenic shock (18%) but were less likely to receive invasive angiography (78%) (all p < 0.001 relative to control patients). Among COVID+ patients who received angiography, 71% received PPCI and 20% received medical therapy (both p < 0.001 relative to control patients). The primary outcome occurred in 36% of COVID+ patients, 13% of PUIs, and 5% of control patients (p < 0.001 relative to control patients). CONCLUSIONS: COVID+ patients with STEMI represent a high-risk group of patients with unique demographic and clinical characteristics. PPCI is feasible and remains the predominant reperfusion strategy, supporting current recommendations.

P atients with cardiovascular disease are more susceptible to severe forms of coronavirus disease 2019 (COVID- 19) infection (1, 2) . Myocardial injury, detected by biomarkers of cardiac damage or cardiac magnetic resonance, is highly prevalent (20% to 30%) among hospitalized patients with COVID-19 infection (3, 4) . Myocardial injury may present with electrocardiographic features of STsegment elevation myocardial infarction (STEMI) (5) .

The management of these patients is controversial, with some advocating a shift to pharmacological reperfusion to mitigate delays in reperfusion and to protect essential health care workers and resources (6) . However, this strategy has been associated with delays in reperfusion, increased mortality, and risk of heart failure (7) . Furthermore, these patients more frequently have no culprit lesion on angiography and therefore are not expected to benefit from pharmacological reperfusion while being exposed to potentially harmful side effects associated with thrombolysis. The prognosis of STEMI patients with COVID-19 infection is highly variable, with reported in-patient mortality ranging from 12% to 72% (7) (8) (9) (10) (11) (12) .

In order to fill these gaps in knowledge, the Society for Cardiovascular Angiography and Table 1 . 

A total of 230 COVID-confirmed cases (COVIDþ) and 495 COVID-suspected cases (PUI) were enrolled from April 28, 2020, and were compared with 460 age-and sex-matched control patients. Baseline characteristics are presented in Table 1 . COVIDþ patients were typically male (71%) and between 56 and 75 years of age. The majority of COVIDþ patients were ethnic minorities (23% Hispanics, 24% Blacks, 6% Asians), with Whites representing only 39% of patients. Dyspnea was the most common presenting symptom (54%), and 46% of patients had infiltrates on chest xray film ( Table 2) . A significant proportion of COVIDþ patients presented with high-risk pre-PCI conditions, including cardiogenic shock (18%) and cardiac arrest (11%) ( Table 2) . was higher for those who did not undergo coronary angiography (n ¼ 24 of 50, 48%) versus those who did (n ¼ 49 of 179, 28%) (p ¼ 0.006). COVIDþ patients also had longer length of stay and intensive care unit stay ( Table 3) . 

Factors associated with COVID-19-related death using OpenSAFELY

Prevalence and impact of myocardial injury in patients hospitalized with COVID-19 infection

Cardiac troponin for assessment of myocardial injury in COVID-19: JACC Review Topic of the Week

Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19)

ST-elevation myocardial infarction in patients with COVID-19: clinical and angiographic outcomes

Reperfusion of ST-segment-elevation myocardial infarction in the COVID-19 era: business as usual?

Management and outcomes of patients with STEMI during the COVID-19 pandemic in China

STsegment elevation in patients with Covid-19 -a case series

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

High thrombus burden in patients with COVID-19 presenting with ST-segment elevation myocardial infarction

Changes in characteristics and management among patients with ST-elevation myocardial infarction due to COVID-19 infection

Characteristics and outcomes in patients presenting with COVID-19 and ST-segment elevation myocardial infarction

North American COVID-19 ST-Segment-Elevation

Myocardial Infarction (NACMI) registry: rationale, design, and implications

The Midwest ST-elevation myocardial infarction consortium: design and rationale

Management of Acute Myocardial Infarction During the COVID-19 Pandemic: A Position Statement From the Society for Cardiovascular Angiography and Interventions (SCAI), the American College of Cardiology (ACC), and the American College of Emergency Physicians (ACEP)

Reduction in ST-segment elevation cardiac catheterization laboratory activations in the United States during COVID-19 pandemic

Considerations for cardiac catheterization laboratory procedures during the COVID-19 pandemic perspectives from the Society for Cardiovascular Angiography and Interventions Emerging Leader Mentorship (SCAI ELM) Members and Graduates

Ventricular septal rupture complicating delayed acute myocardial infarction presentation during the COVID-19 pandemic

Back to the future" for STEMI?: the COVID-19 experience

KEY WORDS COVID-19, outcomes, ST-segment myocardial infarction APPENDIX For expanded Methods and Results sections as well as a supplemental table